KR101214433B1 - 축합 헤테로환 유도체, 그것을 함유하는 의약 조성물 및 그의약 용도 - Google Patents

축합 헤테로환 유도체, 그것을 함유하는 의약 조성물 및 그의약 용도 Download PDF

Info

Publication number
KR101214433B1
KR101214433B1 KR1020067019362A KR20067019362A KR101214433B1 KR 101214433 B1 KR101214433 B1 KR 101214433B1 KR 1020067019362 A KR1020067019362 A KR 1020067019362A KR 20067019362 A KR20067019362 A KR 20067019362A KR 101214433 B1 KR101214433 B1 KR 101214433B1
Authority
KR
South Korea
Prior art keywords
group
alkyl
inhibitors
alkoxy
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020067019362A
Other languages
English (en)
Korean (ko)
Other versions
KR20060132737A (ko
Inventor
노부히코 후시미
히데키 후지쿠라
마사유키 이사지
Original Assignee
깃세이 야쿠힌 고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 깃세이 야쿠힌 고교 가부시키가이샤 filed Critical 깃세이 야쿠힌 고교 가부시키가이샤
Publication of KR20060132737A publication Critical patent/KR20060132737A/ko
Application granted granted Critical
Publication of KR101214433B1 publication Critical patent/KR101214433B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020067019362A 2004-03-04 2006-09-20 축합 헤테로환 유도체, 그것을 함유하는 의약 조성물 및 그의약 용도 Expired - Fee Related KR101214433B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004061429 2004-03-04
JPJP-P-2004-00061429 2004-03-04
PCT/JP2005/004152 WO2005085265A1 (ja) 2004-03-04 2005-03-03 縮合ヘテロ環誘導体、それを含有する医薬組成物およびその医薬用途

Publications (2)

Publication Number Publication Date
KR20060132737A KR20060132737A (ko) 2006-12-21
KR101214433B1 true KR101214433B1 (ko) 2012-12-21

Family

ID=34918063

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020067019362A Expired - Fee Related KR101214433B1 (ko) 2004-03-04 2006-09-20 축합 헤테로환 유도체, 그것을 함유하는 의약 조성물 및 그의약 용도

Country Status (16)

Country Link
US (1) US7732596B2 (https=)
EP (1) EP1724277A4 (https=)
JP (1) JP5078350B2 (https=)
KR (1) KR101214433B1 (https=)
CN (1) CN1934122B (https=)
AU (1) AU2005219777B2 (https=)
CA (1) CA2557320C (https=)
IL (1) IL177513A (https=)
MA (1) MA28512B1 (https=)
NO (1) NO20064412L (https=)
NZ (1) NZ549219A (https=)
PL (1) PL381247A1 (https=)
RU (1) RU2387663C2 (https=)
TW (1) TW200540167A (https=)
WO (1) WO2005085265A1 (https=)
ZA (1) ZA200606792B (https=)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103030617A (zh) 2004-03-16 2013-04-10 贝林格尔.英格海姆国际有限公司 吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法
DE602005009745D1 (de) 2004-12-16 2008-10-23 Boehringer Ingelheim Pharma Glucopyranosyl-substituierte benzen-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
JP5264183B2 (ja) 2005-02-23 2013-08-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコピラノシル置換（（ヘテロ）アリールエチニル−ベンジル）−ベンゼン誘導体及びナトリウム依存性グルコース共輸送体２（ｓｇｌｔ２）インヒビターとしてのそれらの使用
ATE453656T1 (de) 2005-04-15 2010-01-15 Boehringer Ingelheim Int Glucopyranosyl-substituierte (heteroaryloxy- benzyl)-benzen-derivate als sglt-inhibitoren
US7723309B2 (en) 2005-05-03 2010-05-25 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
UA91546C2 (uk) 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
AR054871A1 (es) 2005-07-27 2007-07-25 Boehringer Ingelheim Int Derivados de (hetero)cicloalquiletinil-bencil)-benceno sustituidos con glucopiranosilo, medicamentos que contienen dichos compuestos, sus uso y proceso para su fabricacion
WO2007025943A2 (en) 2005-08-30 2007-03-08 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
AU2006289093A1 (en) 2005-09-08 2007-03-15 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(beta-D-glucopyranos-1-yl)-2-(4-ethynyl-benzyl)-benzene, methods for its preparation and the use thereof for preparing medicaments
AR056195A1 (es) 2005-09-15 2007-09-26 Boehringer Ingelheim Int Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos
AR059489A1 (es) 2006-02-15 2008-04-09 Boehringer Ingelheim Vetmed Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
PE20080697A1 (es) 2006-05-03 2008-08-05 Boehringer Ingelheim Int Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
TWI432446B (zh) 2006-07-27 2014-04-01 Chugai Pharmaceutical Co Ltd 稠環螺酮縮醇衍生物、及其做為糖尿病治療藥之使用
TWI403516B (zh) 2006-07-27 2013-08-01 Chugai Pharmaceutical Co Ltd To replace spirocyclic alcohol derivatives, and its use as a therapeutic agent for diabetes
TWI499414B (zh) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc 鈉與葡萄糖第２型共同運輸體（ｃｏ-ｔｒａｎｓｐｏｒｔｅｒ ２）的抑制物與其應用方法
AU2007307544A1 (en) 2006-10-13 2008-04-17 Chugai Seiyaku Kabushiki Kaisha Thioglucose spiroketal derivative and use thereof as therapeutic agent for diabetes
CN100586932C (zh) * 2007-01-26 2010-02-03 中国医学科学院医药生物技术研究所 抗肿瘤化合物及其制备方法
US7846945B2 (en) * 2007-03-08 2010-12-07 Lexicon Pharmaceuticals, Inc. Piperdine-based inhibitors of sodium glucose co-transporter 2 and methods of their use
CL2008002427A1 (es) 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
AU2009286380B2 (en) * 2008-08-28 2011-09-15 Pfizer Inc. Dioxa-bicyclo[3.2.1.]octane-2,3,4-triol derivatives
DK2396005T3 (da) 2009-02-13 2026-02-09 Boehringer Ingelheim Int Sglt2 hæmmer til at forbedre glykæmisk kontrol
JP5685550B2 (ja) 2009-02-13 2015-03-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｓｇｌｔ２阻害剤、ｄｐｐ−ｉｖ阻害剤、更に必要により抗糖尿病薬を含む医薬組成物及びその使用
EA020798B1 (ru) 2009-09-30 2015-01-30 Бёрингер Ингельхайм Интернациональ Гмбх СПОСОБ ПОЛУЧЕНИЯ КРИСТАЛЛИЧЕСКОЙ ФОРМЫ 1-ХЛОР-4-(β-D-ГЛЮКОПИРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГИДРОФУРАН-3-ИЛОКСИ)БЕНЗИЛ]БЕНЗОЛА
PT2486029E (pt) 2009-09-30 2015-10-14 Boehringer Ingelheim Int Processos para a preparação de derivados de benzil-benzeno substituídos com glucopiranosilo
UY32919A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
BR112012008924A2 (pt) 2009-10-20 2019-09-24 Novartis Ag derivado de glicosídeo e usos do mesmo
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
RS53827B1 (sr) 2009-11-02 2015-06-30 Pfizer Inc. Derivati dioksa-biciklo[3.2.1]oktan-2,3,4-triola
AR079438A1 (es) 2009-12-09 2012-01-25 Panacea Biotec Ltd Derivados de azucar, composiciones farmaceuticas y sus usos
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
US8614195B2 (en) 2011-04-14 2013-12-24 Novartis Ag Glycoside derivatives and uses thereof
JP2014510782A (ja) 2011-04-14 2014-05-01 ノバルティス アーゲー グリコシド誘導体およびその使用
US9018249B2 (en) 2011-09-13 2015-04-28 Panacea Biotec Limited SGLT inhibitors
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
TR201901110T4 (tr) 2013-04-05 2019-02-21 Boehringer Ingelheim Int Empagliflozinin terapötik kullanımları.
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HK1213818A1 (zh) 2013-04-05 2016-07-15 勃林格殷格翰国际有限公司 依帕列净的治疗用途
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
EP4678242A3 (en) 2013-04-18 2026-03-18 Boehringer Ingelheim International GmbH Pharmaceutical composition, methods for treating and uses thereof
WO2015043473A1 (en) * 2013-09-25 2015-04-02 Sunshine Lake Pharma Co., Ltd. Glucopyranosyl derivatives and their uses in medicine
KR20190084096A (ko) 2016-11-10 2019-07-15 베링거 인겔하임 인터내셔날 게엠베하 약제학적 조성물, 치료 방법 및 이의 용도
CN111405899B (zh) 2017-11-30 2025-05-16 爱杜西亚药品有限公司 用于治疗内皮素相关疾病的4-嘧啶磺酰胺衍生物与sglt-2抑制剂的组合
CN116283895A (zh) * 2023-01-09 2023-06-23 怀化宝华生物科技有限公司 一种2-[2-(噻吩基)乙基]苯甲酸的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002193948A (ja) 2000-10-06 2002-07-10 Sankyo Co Ltd α−置換カルボン酸誘導体を含有する糖尿病治療剤
WO2003000712A1 (en) 2001-06-20 2003-01-03 Kissei Pharmaceutical Co., Ltd. Nitrogenous heterocyclic derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor
JP2003012686A (ja) 2001-07-02 2003-01-15 Kyowa Hakko Kogyo Co Ltd ピラゾール誘導体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5582837A (en) * 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
ES2150941T3 (es) 1992-04-03 2000-12-16 Upjohn Co Aminas biciclicas-heterociclicas eficaces farmaceuticamente.
US5502187A (en) 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
PH12000002657B1 (en) * 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
ATE266409T1 (de) 2000-04-13 2004-05-15 Pfizer Prod Inc Synergistische wirkung von glyburide und milrinone
WO2003087093A1 (en) * 2002-04-08 2003-10-23 Council Of Scientific And Industrial Research Novel glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof
TWI254635B (en) * 2002-08-05 2006-05-11 Yamanouchi Pharma Co Ltd Azulene derivative and salt thereof
ES2363941T3 (es) * 2003-03-14 2011-08-19 Astellas Pharma Inc. Derivados de c-glucósido para el tratamiento de diabetes.
JP2004300102A (ja) 2003-03-31 2004-10-28 Kissei Pharmaceut Co Ltd 縮合複素環誘導体、それを含有する医薬組成物およびその医薬用途
BRPI0508259A (pt) * 2004-03-04 2007-07-31 Kissei Pharmaceutical derivado heterocìclico fundido, composição medicinal contendo o mesmo, e uso medicinal do mesmo

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002193948A (ja) 2000-10-06 2002-07-10 Sankyo Co Ltd α−置換カルボン酸誘導体を含有する糖尿病治療剤
WO2003000712A1 (en) 2001-06-20 2003-01-03 Kissei Pharmaceutical Co., Ltd. Nitrogenous heterocyclic derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor
JP2003012686A (ja) 2001-07-02 2003-01-15 Kyowa Hakko Kogyo Co Ltd ピラゾール誘導体

Also Published As

Publication number Publication date
WO2005085265A1 (ja) 2005-09-15
PL381247A1 (pl) 2007-05-14
CN1934122B (zh) 2010-08-04
JP5078350B2 (ja) 2012-11-21
RU2006131552A (ru) 2008-03-10
US7732596B2 (en) 2010-06-08
IL177513A0 (en) 2006-12-10
NZ549219A (en) 2010-08-27
EP1724277A4 (en) 2012-05-02
JPWO2005085265A1 (ja) 2008-01-17
NO20064412L (no) 2006-12-04
RU2387663C2 (ru) 2010-04-27
AU2005219777B2 (en) 2011-02-03
KR20060132737A (ko) 2006-12-21
TW200540167A (en) 2005-12-16
HK1099556A1 (zh) 2007-08-17
CA2557320C (en) 2013-02-05
AU2005219777A1 (en) 2005-09-15
TWI361190B (https=) 2012-04-01
CA2557320A1 (en) 2005-09-15
MA28512B1 (fr) 2007-04-03
CN1934122A (zh) 2007-03-21
US20070197449A1 (en) 2007-08-23
EP1724277A1 (en) 2006-11-22
ZA200606792B (en) 2007-12-27
IL177513A (en) 2011-11-30

Similar Documents

Publication Publication Date Title
KR101214433B1 (ko) 축합 헤테로환 유도체, 그것을 함유하는 의약 조성물 및 그의약 용도
KR101141558B1 (ko) 축합 복소환 유도체, 그것을 함유하는 의약 조성물 및 그의약 용도
JP4147111B2 (ja) グルコピラノシルオキシピラゾール誘導体およびその医薬用途
KR100985502B1 (ko) 피라졸 유도체,그것을 함유하는 의약 조성물, 그 의약용도 및 그 제조 중간체
ES2383892T3 (es) Derivado heterocíclico condensado, composición medicinal que lo contiene y el uso medicinal del mismo
JP4606876B2 (ja) ピラゾール誘導体、それを含有する医薬組成物及びその医薬用途
JP4679155B2 (ja) 含窒素複素環誘導体、それを含有する医薬組成物およびその医薬用途
JP4651934B2 (ja) ベンジルフェノール誘導体、それを含有する医薬組成物およびその医薬用途
KR101179451B1 (ko) 질소 함유 축합 환 유도체, 그것을 함유하는 의약 조성물및 그 의약 용도
US20070185197A1 (en) Phenol derivative, medicinal composition containing the same, and medicinal use thereof
JPWO2005095372A1 (ja) ナフタレン誘導体、それを含有する医薬組成物及びその医薬用途
JPWO2005095373A1 (ja) ナフタレン誘導体、それを含有する医薬組成物およびその医薬用途
MXPA06009860A (en) Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
HK1099556B (en) Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20151215

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20151215